Last reviewed · How we verify

Zactima — Competitive Intelligence Brief

Zactima (Zactima) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

discontinued AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Zactima (Zactima) — Barbara Ann Karmanos Cancer Institute.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Zactima TARGET Zactima Barbara Ann Karmanos Cancer Institute discontinued AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial
Caprelsa Caprelsa Genzyme, a Sanofi Company marketed AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zactima — Competitive Intelligence Brief. https://druglandscape.com/ci/zactima. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: